Affiliation:
1. Research Institute of Cardiology, Tomsk National Research Medical Center
Abstract
Aim. To study the prognostic significance of inflammatory biomarkers in patients with chronic heart failure (CHF) and stenotic multivessel coronary atherosclerosis, with determination of the biomarker separate set that reflects subclinical inflammation and is associated with the development of cardiovascular complications during prospective observation.Material and methods. A prospective observational study was conducted that included 80 patients with CHF and ischemic heart disease who were scheduled for coronary artery bypass grafting (CABG) during their current hospitalization. In addition to routine clinical laboratory tests, coagulation parameters were evaluated and the following inflammatory biomarkers were determined: neutrophil gelatinase-associated lipocalin (NGAL), growth/differentiation factor 15 (GDF-15), fibroblast growth factor 23 (FGF-23), transforming growth factor beta-1 (TGF-β1), and high-sensitivity C-reactive protein. Also, the calculated neutrophil-to-lymphocyte ratio (N LR) was included in the analysis. Follow-up duration was at least 12 months (median 16 [13, 22] months). Statistical analysis of the data was performed with the IBM SPSS Statistics 21 software.Results. The study presented results of a factor analysis of 10 inflammatory biomarkers in patients who were scheduled for CABG. One of the factors identified by the analysis included the levels of NGAL and GDF-15, N LR, and the level of fibrinogen in the blood in CHF patients with stenotic coronary atherosclerosis and was significantly associated with the death rate during prospective observation. Furthermore, this association remained significant even after adjustments for age, glomerular filtration rate, severity of heart and coronary insufficiency, and the presence of diabetes mellitus.Conclusion. In patients with CHF and stenotic coronary atherosclerosis, a set of inflammatory markers, including blood NGAL, GDF-15, N LR, and fibrinogen, can be combined into one factor reflecting subclinical inflammation. The value of this factor can be used to predict cardiovascular death in the long term after surgical myocardial revascularization.
Publisher
APO Society of Specialists in Heart Failure
Reference21 articles.
1. Tereshchenko S.N., Galyavich A.S., Uskach T.M., Ageev F.T., Arutyunov G.P., Begrambekova Yu.L. et al. 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):311–74. DOI: 10.15829/1560-4071-2020-4083
2. Garganeeva A.A., Kuzheleva E.A., Kuzmichkina M.A., Ryabov V.V., Mareev Yu.V., Mareev V.Yu. Characteristics and treatment of patients with heart failure admitted to a cardiology department in 2002 and 2016. Kardiologiia. 2018;58(12S):18–26. DOI: 10.18087/cardio.2605
3. Ageev F.T., Skvortsov A.A., Mareev V.Yu., Belenkov Yu.N. Heart failure on the background of coronary heart disease: some issues of epidemiology, pathogenesis and treatment. Russian Medical Journal. 2000;8(15):622–6.
4. Shirazi LF, Bissett J, Romeo F, Mehta JL. Role of Inflammation in Heart Failure. Current Atherosclerosis Reports. 2017;19(6):27. DOI: 10.1007/s11883-017-0660-3
5. Kuzheleva E.A., Fedyunina V.A., Garganeeva A.A. Patterns of immunological reactions in the pathogenesis of chronic heart failure: review. Kardiologiia. 2021;61(12):94–104. DOI: 10.18087/cardio.2021.12.n1598
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献